PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of postmedjPostgraduate Medical JournalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Postgrad Med J. 2007 June; 83(980): 395–401.
PMCID: PMC2600041

Management of end stage cardiac failure

Abstract

Optimum heart failure medication and an increasing array of interventions have had an enormous effect on morbidity and mortality over the past 10 years. However, patients with end stage disease can still be highly symptomatic. Moreover, such patients are disadvantaged compared with patients with malignant disease. They are less likely to have an understanding of their illness or have access to supportive care. They are also less likely to have the opportunity to plan for care with regard to death and dying. There is increasing demand that the multi‐professional clinical team gain good communication and supportive care skills, and that appropriate access to specialist palliative care services is available.

Over the last 10 years, there has been a realisation that heart failure (itself the final common pathway of several aetiologies such as hypertension, ischaemic and valvular heart disease, and cardiomyopathy) is a terminal illness. Although advances in treatment have made a major impact on the clinical course and prognosis, patients may still experience debilitating problems in the end stage of their disease, and are less likely to have access to supportive and palliative care services than patients with malignant disease.1,2,3,4,5,6 They are also less likely to understand what their illness is and to have had an opportunity to discuss matters relating to death and dying with their professional or informal carers; this means they are less likely to have the opportunity to plan for this event and are more likely to die in hospital.6,7

Several studies have demonstrated the symptom burden of these patients, and some have compared this to patients with cancer and shown that the symptom load is similar.1,2,8 Basic supportive and palliative care skills are therefore required by the heart failure patient's usual health care professionals in both primary and secondary care, and access to specialist palliative care services for those with complex problems enabled. The need for a palliative care approach and access to specialist palliative care (SPC) services has been underlined in the National Service Framework for heart failure, National Institute for Health and Clinical Excellence guidance, and subsequent Department of Health guidance on service development for heart failure.9,10,11

EVIDENCE BASE

Although there is mounting qualitative evidence to demonstrate the burden of heart failure, there is very little literature to provide an evidence base for symptom control in heart failure. Although there is grade A evidence to support optimum cardiac medication, it is not within the scope of this article to discuss this although I will give a few key references for each.

For the symptom control issues, I include what research there is; there are few randomised controlled studies, and what little there are tend to be small, or pilot studies as shown in table 11.. However, there is an increasing base of experience from those working with the palliation of heart failure patients, much of which is transferred from the field of oncology. There is much need for research in this area.

Table thumbnail
Table 1 Evidence for breathlessness in heart failure

There is also little evidence to indicate which model of service is best suited to provide supportive and palliative care, but there are some services that have described their experience and I have therefore referred to these.

SYMPTOMS

The principles of symptom control are the same irrespective of diagnosis. A full assessment of the patient (including relevant investigations), intervention to reverse any reversible factors and palliation of irreversible situations is a system which is applicable to oncology and heart patients alike. Failure to apply these principles, however, results in conflicting management plans and inappropriate treatments that can aggravate the situation and confuse the patient and their carers. Continuity of care is also very important and can be a problem for many patients who may be seen by a variety of healthcare professionals even within the same setting.1 Good communication with patient and carer, and good communication between secondary and primary care is an integral part of effecting symptom control.

Principles of symptom management: summary

  • Perform a holistic assessment of cause of symptoms
  • Optimise tolerated cardiac medication
  • Reverse any reversible factors
  • Palliate any remaining symptoms

Physical

Optimal medical management

It is important that the medical management of heart failure is optimised as this has a major effect not only on survival but also on symptom control. This should be reviewed regularly.

Angiotensin‐converting enzyme inhibitors (ACE‐I) or angiotensin II inhibitors (AII‐I) are the mainstay of pharmacological treatment and should be continued if tolerated.12,13,14,15,16,17,18 The main difficulties, particularly towards end stage disease, are hypotension and renal dysfunction. The latter may often be rectified by judicious titration of loop diuretic, or dose reduction of the ACE‐I. However, towards end stage a balance between the need for symptom control, especially symptoms due to fluid overload, and renal function is often required, and a degree of renal dysfunction accepted.

Likewise, appropriate use of loop diuretics is standard. Education of the patient to enable them to use a weight management programme with altered diuretic dose if necessary can reduce the number of hospital admissions due to decompensation. Low dose (25 mg/day) spironolactone has been shown to increase survival and can improve symptoms of peripheral oedema.19 Hyperkalaemia is the main reason for stopping it, but nausea can also be a problem in some. The newer drug eplerenone is thought to cause less hyperkalaemia, but it is not yet widely used.20 It is currently only licensed for left ventricular dysfunction post‐myocardial infarction, but in end stage disease, a clinical judgement could be made to assess whether it would be useful in other aetiologies. Patients may also require additional diuretics such as bendroflumethiazide or metolazone in order to control peripheral or pulmonary oedema. Metolazone is a very powerful diuretic which may not have its optimal response for a few days. It therefore requires close monitoring and clear prescribing responsibility, especially on discharge from hospital if it has been started as an inpatient. Often a dose as small as 2.5 mg twice a week is enough.

β‐blockers are also part of optimal treatment, although hypotension may limit their use.21,22,23 Reversible airways disease is a contraindication, but many patients with chronic obstructive pulmonary disease (COPD) can tolerate them.

Digoxin can also be useful; however, unless the patient is in atrial fibrillation, it can usually be stopped in end stage disease in order to minimise tablet burden.

Some patients are eligible for interventions such as biventricular pacing and resynchronisation (especially for patients with wide complexes on ECG) and/or implantable cardioverter‐defibrillator (ICD) devices, and cardiology expertise should be sought.24,25

Many patients are not on optimal tolerated management, either because they have not been assessed in this regard, or because medication has been stopped for a transient problem, and not restarted. For example, an ACE‐I may have been stopped because the patient had some renal dysfunction due to overdiuresis, but not re‐started when the problem was resolved, and indeed may not have needed to have been stopped in the first place. Those who are on such medication may not be on the optimum dose.

Titration of optimal treatment is a skilled process and involvement of a heart failure nurse specialist and cardiology review is often very helpful.

Optimum cardiac management: summary

Review with regard to

  • ACE‐I or AII‐I
  • β‐blocker
  • Spironolactone
  • Optimise other diuretics
  • Resynchronisation or ICD

Breathlessness

Breathlessness is common and its severity provides the basis for the New York Heart Association (NYHA) classification of heart failure. Assessment should look for the cause of breathlessness such as pulmonary oedema from decompensated heart failure with fluid overload, chest infection, pleural effusion (which itself could be due to fluid overload or infection, pulmonary embolism or underlying bronchogenic cancer), pulmonary embolism or neoplasm. Many patients with heart failure also have co‐existent COPD or asthma as a contributory cause of their breathlessness.

However, many patients who do not have any other cause of breathlessness and who are at their dry weight will be breathless on exertion. It is thought that this is due to increased chemoceptor sensitivity and an increased muscle ergoreflex response. Moreover, the pattern of respiration and lung perfusion/ventilation is inefficient, resulting in increased physical and physiological dead space.26

Oxygen would seem an obvious choice to alleviate breathlessness, but as decompensated patients tend not to desaturate, it does not appear to be of benefit unless there are other factors causing hypoxia. A patient by patient assessment should be made rather than automatic use of expensive and potentially intrusive and psychological dependence inducing treatment.27,28,29,30

Non‐pharmacological interventions such as pacing and prioritising, management of panic and breathing training are likely to be helpful and have been shown to be beneficial in lung cancer and COPD patients.31 Likewise a hand‐held fan can provide useful cool air to the face, alleviating the sensation of breathlessness to a certain degree.32

There is a small amount of evidence in support of opioids for the treatment of breathlessness.33,34,35,36 A randomised placebo controlled crossover pilot study showed a statistically significant improvement in breathlessness scores with morphine.35 It was generally well tolerated for the 4‐day treatment period and some of the patients have stayed on it long term for some years. Oxycodone has theoretical and anecdotal advantages over morphine because it does not have pharmacologically active metabolites to accumulate in renal dysfunction, which is the case with morphine. Obviously careful monitoring is required if opioids are used, with dose reduction and dosage interval increase in renal dysfunction. Because of the likelihood of variable renal function in end stage disease, it would seem sensible to use immediately available preparations rather than sustained release ones. As a general rule, a dose range of 2.5–5 mg of morphine, or 1–2 mg of oxycodone up to four times a day is sufficient to help with breathlessness. If a patient is also in pain, then the dose may need to be titrated higher. Patients commenced on opioids should also have an anti‐emetic prescribed as nausea may be a problem, at least for the first few days, and a laxative as the vast majority of patients will become constipated. Counselling of the patient is also important as many have fears relating to opioids, thinking that taking them equates with imminent death, or even an underlying undeclared diagnosis of cancer. Reassuring the patient that the aim is to help them increase their mobility and function may increase their compliance.

There is an account of the use of nebulised morphine in two patients,36 but this route should not be used unless there were greater evidence of safety and efficacy.

Where panic is a major contributory factor, a benzodiazepine can be helpful if non‐pharmacological measures have failed. Anecdotally, respiratory depression does not appear to be the major concern once thought. However, benzodiazepines are associated with a higher risk of falling, and can impair short term memory. An intermediate half‐life preparation such as lorazepam (which also has the advantage of being able to be absorbed sublingually for quicker effect) is therefore likely to be preferable to longer acting ones such as diazepam. There is no published research to guide the clinician and decisions should be taken on an individual basis.

Management of breathlessness: summary

  • Assess cause, looking for “reversible” factors—for example, optimise management of co‐morbidity such as asthma
  • Non‐pharmacological methods of breathlessness management, including hand held fan
  • Opioids
  • Cautious use of benzodiazepines for panic
  • Oxygen if appropriate (ie, hypoxia)

Pain

Heart failure is not commonly thought of as a painful condition, but yet many patients experience pain. This may be angina, claudication or pain due to gout, arthritis, muscular pain, or even co‐existent diabetic neuropathy. Sometimes patients can complain of pain in the legs, often at night, not associated with claudication or night cramps that has the characteristics of neuropathic pain, and anecdotally often responds to low dose neuropathic adjuvant analgesics such as gabapentin.

Assessment with application of the World Health Organization analgesic ladder (table 22)37 is appropriate even though it was developed for cancer pain. Optimal anti‐anginal treatment is important, and in resistant angina, there is some evidence for the use of opioids, TENS (transcutaneous electrical nerve stimulation) or even spinal cord stimulation in selected patients if available.38,39,40,41,42,43 Non‐steroidal anti‐inflammatory drugs should be avoided as there is an increased risk of decompensation with their use.44 Instead, colchicine followed by allopurinol (as it may recur if the dose of diuretic is changed) should be used to treat gout; occasionally cautious use of low dose steroids may be needed, but there is a risk of fluid retention with this too. If neuropathic adjuvants are needed, then amitriptyline should not be used because of the increased risk of arrhythmias.

Table thumbnail
Table 2 The World Health Organization analgesic ladder

Fatigue

Fatigue is also a major problem in patients with heart failure. Again, an assessment to look for potentially reversible factors is essential. Hypokalaemia from loop diuretics, anaemia, and over diuresis are all common. Patients on β‐blockers, particularly initially, may find fatigue a problem. A sleep history should be taken as many patients suffer insomnia. This could be due to paroxysmal nocturnal dyspnoea in the decompensated patient, or orthopnoea. A simple intervention such as raising the patient's feet in bed (this may need a hospital bed to be arranged at home) can sometimes result in better sleep as the patient no longer slips down the bed during the night. Periodic respiration is also a problem in some, and is thought to be due to the hypersensitive chemoceptors. Oxygen therapy and dihydrocodeine have both been shown to ameliorate this.45 A small dose of opioid at bed time may therefore by helpful. If there is sleep apnoea, then nocturnal non‐invasive ventilation may be helpful. Depression is discussed later, but may also be a reversible cause of fatigue.

Causes of fatigue in heart failure: summary

Drug causes

  • Overdiuresis
  • Hypokalaemia from loop diuretics
  • β‐blockers
  • Blood loss due to aspirin

Anaemia

  • See aspirin
  • Anaemia of chronic disease
  • Co‐morbidities—for example, pernicious anaemia, malignancy

Sleep problems

  • Orthopnoea
  • Paroxysmal nocturnal dyspnoea
  • Periodic respiration ± sleep apnoea
  • Anxiety/depression

Psychological

  • Depression
  • Anxiety

Other symptoms

Nausea and vomiting may be caused by medication (spironolactone, digoxin toxicity, opioids), liver capsule distension, gut wall oedema, constipation or renal failure. Anxiety may also play a part. Again reversible factors should be addressed and an anti‐emetic given while needed. Cyclizine should be avoided because of its strong anticholinergic effect.46 Prokinetics such as metoclopramide or domperidone seem well tolerated, as are haloperidol and levomepromazine, especially if the dose is kept low (for example, 0.5–1.5 mg haloperidol daily or 6 mg levomepromazine once or twice daily). Attention to nutritional state is important as many patients do not eat well47; however, as the end stage of disease is reached, a cachexic metabolic state often supervenes, in which case, emphasis on eating little and often can relieve the burden of “trying to get enough food down”. Anti‐cytokine approaches such as thalidomide may help at this stage, but currently its use is experimental.

Skin care is important as cellulitis is a risk with swollen legs. Regular use of emollients such as aqueous cream is helpful. If itch is a problem, the addition of menthol to the aqueous cream can provide a useful cooling effect. If itch persists, then selective serotonin reuptake inhibitors (SSRIs), or 5‐hydroxy tryptamine 3 inhibitors such as ondansetron may give some benefit; thalidomide may also help.48,49,50,51,52 A sedative antihistamine may help sleep, but antihistamines are often disappointing in this situation.

As patients are often on a degree of fluid restriction, constipation should not be managed with bulking agents such as ispaghula husk, unless there is a good reason such as irritable bowel or diverticular disease. Macroglycols seem well tolerated and not all commercially available preparations (for example, Idrolax) have high sodium content.

Table 33 lists those drugs to avoid, if possible, when attempting to control other symptoms in heart failure.

Table thumbnail
Table 3 Drugs to avoid if possible in symptom control in heart failure

Psychological/spiritual/social/financial

As discussed above, there is an increasing wealth of published patient narrative from well constructed qualitative research demonstrating the impact that heart failure has on quality of life; the problems affecting every domain of life. Depression is common and has an independent effect on morbidity and mortality from heart failure.53,54 Tricyclics should be avoided, but SSRIs appear to be safe although some have more drug interactions than others, which is important to take into consideration when so many patients are on warfarin.55 Non‐pharmacological approaches using cognitive behavioural therapy or exercise training can be beneficial.56,57

The meaning of life, fears and questions about death and dying, and the ever shrinking social parameters become big issues.1 Eventually individuals may become house bound and feel a burden upon their carers. Struggling with polypharmacy, co‐morbidity and a health and social care system that can appear bemusing and may offer less than perfect continuity, it can be hard to maintain hope and purpose.

A full holistic assessment is therefore mandatory, ensuring that the relevant members of the team, including physiotherapy, occupational therapy, social worker and spiritual care, are involved. The primary care team and heart failure nurse specialist, if there is one, are invaluable in ensuring these aspects do not get forgotten and management is maximised even in the midst of progressing disease.

SPECIFIC END‐OF‐LIFE ISSUES

Prognosis

One of the barriers to accessing SPC services results from the difficulties with prognosis. Apart from the risk of sudden death due to arrhythmia or myocardial infarction, the trajectory of disease is one of slow decline interspersed with episodes of decompensation. Initially these episodes are typically precipitated by infection, or a further ischaemic event, but later on can happen without any obvious reason. It can be very difficult to predict which episode of decompensation will respond to treatment. Various features of disease, such as levels of B‐type natriuretic protein or serum sodium, have been looked at as prognostic markers, but this work is beyond the scope of this article.

The problem is more significant if there is the persistent misconception that SPC services are only appropriate for patients at the very end of life, who are actively dying. Over the past 30 years, in the field of oncology, SPC services have been used earlier and earlier in a patient's illness if there are issues best dealt with by them. Whether the patient is imminently terminal (which can sometimes be just as difficult to determine in oncology) has become less of a barrier to referral. Therefore, in heart failure patients, if a problem approach is used alongside discussion with the patient regarding their wishes, then it can be possible to involve SPC services when there is a problem with which they can help (for example, symptom control, day hospice attendance, admission for intravenous diuretic management when appropriate). The patient can then be discharged if they stabilise and no longer require SPC input. Using a holistic, multiprofessional approach, many of the supportive and palliative care issues will be managed by the patient's usual medical team who will then be aware of difficult problems that need referral on to the specialist team. In this way, patient problems will be assessed and addressed in a timely fashion, rather than referring to SPC services too late. This is a particular issue for patients awaiting transplant who have traditionally not been referred to SPC services because they are still aiming for active treatment; there is no reason why both approaches cannot be used in this highly symptomatic group and be discharged from SPC services if there is a successful transplant.

In order for this to happen, the usual medical team will require sufficient communication skills in order to discuss difficult issues with the patient and family; some may feel inadequate to this task and training may be required.

Some cardiac networks have drawn up referral and symptom control guidance to help this process.58 The Gold Standards Framework (GSF) is a primary care initiative to help with advanced planning and care for palliative care patients.59 The GSF and Coronary Heart Disease Collaborative guidance60 for when to include heart failure patients on the palliative care list can be seen in box 1.

Box 1 Global Standards Framework (GSF) guidance for including heart failure patients59,60

Suggested criteria for inclusion on the Supportive Care Register for a patient with heart failure can be found in “Coronary Heart Disease Collaborative Supportive and Palliative Care for Advanced Heart Failure” 2005 www.modern.nhs.uk/chd.60 In the guidance document suggested criteria for inclusion of patients with heart failure on the GSF Supportive Care register include two or more of the following:

  • CHF NYHA functional class III or IV
  • Thought to be in the last year of life
  • Repeated hospital admissions with symptoms of heart failure
  • Patient has difficult physical/psychological symptoms despite optimal tolerated therapy

CHF, chronic heart failure; NYHA, New York Heart Association.

Care and planning at the end of life

Communication skills are the key factor. Discovering a patient's wishes about quality and quantity of life can be hard. However, if this is not done, the patient may well die in hospital “by default” when that would not have been their wish. Transferring systems of care pioneered in cancer management, such as the GSF, and the Liverpool Care Pathway for the Dying (which is a checklist for care aiming to bring hospice care to other settings such as hospital and home), can allow advanced planning and support to be provided, leading to a dignified and comfortable death in the place of patient choice.61

Do not resuscitate orders and ICDs

Other areas requiring skilful communication include do not resuscitate orders and arranging for ICDs to be switched to pacemaker mode.

The latter needs sensitive discussion in enough time to arrange the pacemaker technician (or sometimes the company representative) to re‐programme the device. Facilities and systems vary for this in different localities and it is recommended that the clinical team is familiar with local procedures. Some areas do not have guidance about this and relevant clinicians should be encouraged to rectify this. Potential repeated shocks in clear consciousness in a dying patient are distressing for all. Strong magnets usually available from the pacemaker clinic held over the device should prevent it from activating; however, this only works while it is held next to the device and is therefore not a replacement plan for re‐programming.

Ethically, this is considered to be withholding or withdrawing treatment and there is some useful discussion in the literature.62,63,64 Even in the event of an asystolic death, the ICD should be switched to pacing mode before removal by the mortician as anecdotally there is a risk of a shock to staff during this procedure.

Specific symptom issues in the dying

The skills required to care for the dying learnt in oncology are transferable to heart failure patients. The only significant differences, apart from the issue of devices, is that despite the patient drinking less and less (thus in effect fluid restricting) pulmonary oedema can still be a distressing problem for some. Intravenous administration of diuretic can be intrusive and uncomfortable, particularly where venous access has become difficult, and intramuscular injections are unpleasant. Subcutaneous administration of furosemide appears to be possible and effective either by intermittent injection or continuous infusion with a syringe driver.65,66 If the oral route is lost, transdermal nitrates may also be useful to help prevent pulmonary oedema. Again, the counsel of perfection is to avoid anticholinergics such as cyclizine, and there are appropriate anti‐emetic alternatives. The use of anticholinergics to ease severe “death rattle” in patients who are actively dying is less avoidable, but less of a concern at this stage.

Key references

  • Murray SA, Boyd K, Kendall M, et al. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 2002;235:929–34.
  • Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure – a pilot study. Eur J Heart Failure 2002;4:753–6.
  • Mueller PS, Hook CC, Hayes DI. Ethical analysis of withdrawal of pacemaker or implantable cardioverter –defibrillator support at the end of life. Mayo Clin Pract 2003;78:959–63.
  • Johnson MJ, Houghton T. Palliative care for patients with heart failure: description of a service. Palliat Med 2006;20:211–14.
  • Supportive and Palliative Care in Heart Failure: a resource kit for cardiac networks. Heart Improvement Programme. www.heart.nhs.uk. Available from: NHS Health Improvement Programme 3rd floor, St John's House, East Street. Leicester LE1 6NB, UK

BARRIERS TO ACCESSING SPECIALIST PALLIATIVE CARE SERVICES

There are many barriers to patients accessing SPC services or even generic care from their primary teams; these are summarised in table 5.67,68,69,70,71,72,73,74 There is progress in the UK but it is patchy.

CONCLUSIONS

Patients with heart failure are as symptomatic as many patients with cancer but still do not have equal access to supportive and palliative care, either from their own team or from SPC services.75 There is a need for all practitioners involved in their care to develop skills that include a full holistic assessment of symptoms, teamwork and an ability to communicate effectively with patient, carer and other health care professionals. A useful resource has been developed by the Heart Improvement Programme.76 Recognition of patients who are in the end stage of their illness is important to allow appropriate discussion, choice and planning for the patient and family. The difficulties in prognosis make this challenging, but not impossible, in a significant number of patients. The developing links between cardiology, palliative care and primary care is to be fostered, with mutual learning and understanding contributing to better care of the patients.

MULTIPLE CHOICE QUESTIONS (TRUE (T)/FALSE (F); ANSWERS AFTER THE REFERENCES

  1. Depressed patients with heart failure have an increased mortality.
  2. When prescribing opioids, ispaghula husk should be co‐prescribed to prevent constipation.
  3. Oxygen is usually useful in the management of breathlessness in stable heart failure patients.
  4. Re‐programming an ICD to pacemaker mode is an equivalent decision to a do not resuscitate order.
  5. Anticholinergic drugs are helpful in the management of nausea in heart failure patients.
  6. Patients with cancer have easier access to SPC services than heart failure patients.
  7. SPC services are only appropriate for patients who are in the last few weeks of life.

Abbreviations

ACE‐I - angiotensin‐converting enzyme inhibitors

AII‐I - angiotensin II inhibitors

COPD - chronic obstructive pulmonary disease

GSF - Gold Standards Framework

ICD - implantable cardioverter‐defibrillator

SPC - specialist palliative care

SSRIs - selective serotonin reuptake inhibitors

TENS - transcutaneous electrical nerve stimulation

ANSWERS

  1. T; (2) F; (3) F; (4) T; (5) F; (6) T; (7) F.

Footnotes

Competing interests: None declared

References

1. Murray S A, Boyd K, Kendall M. et al Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 2002. 235929–934.934 [PMC free article] [PubMed]
2. Anderson H, Ward C, Eardley A. et al The concerns of patients under palliative care and a heart failure clinic are not being met. Palliative Med 2001. 15279–286.286 [PubMed]
3. Levenson J W, McCarthy E P, Lynn J. et al The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000. 48(5 suppl)S101–S109.S109 [PubMed]
4. Nordgren L, Sorensen S. Symptoms experienced in the last six months of life with end‐stage heart failure. Eur J Cardiovasc Nurs 2003. 2213–217.217 [PubMed]
5. Hobbs F D, Kenkre J E, Roalfe A K. et al A cross‐sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002. 231867–1876.1876 [PubMed]
6. Buetow S A, Coster G. Do general practice patients with heart failure understand its nature and seriousness, and want improved information? Patient Educ Couns 2001. 45181–185.185 [PubMed]
7. Rogers A, Addington‐Hall J M, McCoy A S. et al A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur J Heart Fail 2002. 4283–287.287 [PubMed]
8. McKinley R K, Stokes T, Exley C. et al Care of people dying with malignant and cardio‐respiratory disease in general practice. Br J Gen Pract 2004. 54909–913.913 [PMC free article] [PubMed]
9. Department of Health National Service Framework for coronary heart disease – modern standards and service models. London: Department of Health, 2000
10. National Institute for Health and Clinical Excellence Management of chronic heart failure in adults in primary and secondary care. London: NICE, 2003
11. Department of Health Developing services for heart failure. London: Department of Health, 2003
12. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced ejection fractions. N Engl J Med 1992. 327685–691.691 [PubMed]
13. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991. 325293–302.302 [PubMed]
14. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe heart failure. N Engl J Med 1987. 3161429–1435.1435 [PubMed]
15. The Acute Infarction Ramipril Efficiency (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993. 342821–828.828 [PubMed]
16. Granger C B, McMurray J J V, Yusuf S. et al Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: the CHARM‐Alternative trial. Lancet 2003. 362772–776.776 [PubMed]
17. Pfeffer M A, McMurray J J V, Velazquez E J. et al Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003. 3491893–1906.1906 [PubMed]
18. Cohn J N, Tognoni G for the Valsartan Heart Failure Trial Investigators A randomised trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. N Engl J Med 2001. 3451667–1675.1675 [PubMed]
19. Pitt B, Zannad F, Remme W J. et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999. 341709–717.717 [PubMed]
20. Pitt B, Remme W J, Zannad F. et al Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003. 3481309–1321.1321 [PubMed]
21. CIBIS II Investigators The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999. 3539–13.13 [PubMed]
22. Packer M, Bristow M R, Cohn J N. et al The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996. 3341349–1355.1355 [PubMed]
23. MERIT‐HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT‐HF). Lancet 1999. 3532001–2009.2009 [PubMed]
24. Cleland J F, Daubert J C, Erdmann E. et al The effect of cardiac resynchronisation on morbidity and mortality in heart failure. N Engl J Med 2005. 3521539–1549.1549 [PubMed]
25. Moss A J, Hall W J, Cannon D S. et al Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996. 3351933–1940.1940 [PubMed]
26. Clark A L, McDonagh T. The origin of symptoms in chronic heart failure. Heart 1997. 78429–430.430 [PMC free article] [PubMed]
27. Moore D P, Weston A R, Hughes J M. et al Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet 1992. 339850–853.853 [PubMed]
28. Restrick L J, Davies S W, Noone L. et al Ambulatory oxygen in chronic heart failure. Lancet 1992. 3401192–1193.1193 [PubMed]
29. Russell S D, Koshkarian G M, Medinger A E. et al Lack of effect of increased inspired oxygen concentrations on maximal exercise capacity or ventilation in stable heart failure. Am J Cardiol 1999. 841412–1416.1416 [PubMed]
30. Booth S, Wade R, Johnson M J. et al The use of oxygen in the palliation of breathlessness. A report of the Expert Working Group of the Scientific Committee of the Association of Palliative Medicine. Resp Med 2004. 9866–77.77 [PubMed]
31. Moore S, Corner J, Haviland J. et al Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial [erratum: BMJ 2002;325:1386]. BMJ 2002. 3251145 [PMC free article] [PubMed]
32. Schwartzstein R M, Lahive K, Pope A. et al Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987. 13658–61.61 [PubMed]
33. Williams S G, Wright D J, Diesch J P. et al Effect of low dose diamorphine on exercise capacity in patients with chronic heart failure. Heart 2001. 85(Suppl 1)4
34. Chua T P, Harrington D, Ponikowski P. et al Effects of dihydrocodeine on chemosensivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997. 29147–152.152 [PubMed]
35. Johnson M J, McDonagh T A, Harkness A. et al Morphine for the relief of breathlessness in patients with chronic heart failure – a pilot study. Eur J Heart Failure 2002. 4753–756.756 [PubMed]
36. Farncombe M, Chater S. Case studies outlining use of nebulised morphine for patients with end‐stage chronic lung and cardiac disease. J Pain Symptom Manage 1993. 8221–225.225 [PubMed]
37. World Health Organization Cancer pain relief, 2nd ed. Geneva: World Health Organization, 1996. 74
38. Bueno E A, Mamtani R, Frishman W H. Alternative approaches to the medical management of angina pectoris: acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Dis 2001. 3236–241.241 [PubMed]
39. Borjesson M, Eriksson P, Dellborg M. et al Transcutaneous electrical nerve stimulation in unstable angina pectoris. Coronary Artery Disease 1997. 8543–550.550 [PubMed]
40. Mannheimer C, Emanuelsson H, Waagstein F. The effect of transcutaneous electrical nerve stimulation (TENS) on catecholamine metabolism during pacing‐induced angina pectoris and the influence of naloxone. Pain 1990. 4127–34.34 [PubMed]
41. DeJongste M J L, Hautvast R W M, Hillege J L, Lie KI on behalf of the Working Group on Neurocardiology Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris. J Am Coll Cardiol 1994. 231592–1597.1597 [PubMed]
42. Sanderson J E, Brooksby P, Waterhouse D. et al Epidural spinal electrical stimulation for severe angina: a study of its effect on symptoms, exercise tolerance, and degree of ischaemia. Eur Heart J 1992. 13628–633.633 [PubMed]
43. Mannheimer C, Eliasson T, Augustinsson L ‐ E. et al Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris. The ESBY study. Circulation 1998. 971157–1163.1163 [PubMed]
44. Heerdink E, Leufkens H, Herings R. et al NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics Arch Intern Med1998. 1581108–1112.1112 [PubMed]
45. Ponikowski P, Anker S D, Chua T P. et al Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation 1999. 1002418–2424.2424 [PubMed]
46. Tan L B, Bryant S, Murray R G. Detrimental haemodynamic effects of cyclizine in heart failure. Lancet . 1988;i560–561.561 [PubMed]
47. Pasini E, Opasich C, Pastoris O. et al Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure. Am J Cardiol 2004. 9341A–43A.43A [PubMed]
48. Anker S D, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002. 8551–66.66 [PubMed]
49. Davis M P, Frandsen J L, Walsh D. et al Mirtazepine for pruritis. J Pain Symptom Manage 2003. 25288–291.291 [PubMed]
50. Balaskas E V, Bamihas G I, Karamouzis M. et al Histamine and serotonin in uraemic pruritis: effect of ondansetron in CAPD – pruritic patients. Nephron 1998. 78395–402.402 [PubMed]
51. Murphy M, Reaich D, Pai P. et al A randomised, placebo‐controlled, double‐blind trial of ondansetron in renal itch. Br J Dermatol 2003. 148314–317.317 [PubMed]
52. Silva S R, Viana P C, Lugon N V. et al Thalidomide for the treatment of uraemic pruritis; a cross over, randomised, double blind trial. Nephron 1994. 67270–273.273 [PubMed]
53. Murberg T A, Bru E, Svebak S. et al Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two‐years follow up study. Int J Psychiatr Med 1999. 29311–326.326 [PubMed]
54. Guck T P, Elsasser G N, Kavan M G. et al Depression and congestive heart failure. Congestive Heart Failure 2003. 9163–169.169 [PubMed]
55. Alvarez W, Jr, Pickworth K K. Safety of anti‐depressant drugs in the patient with cardiac disease: a review of the literature. Pharmacother 2003. 23754–771.771 [PubMed]
56. Luskin F, Reitz M, Newll K. et al A controlled pilot study of stress management training of elderly patients with congestive heart failure. Prev Cardiol 2002. 5168–172.172 [PubMed]
57. Koukouvou G, Kouidi E, Iacovides A. et al Quality of life, psychological and physiological changes following exercise training in patients with chronic heart failure. J Rehab Med 2004. 3636–41.41 [PubMed]
58. Cheshire & Merseyside Cardiac Network (CMCN) Website http://www.cmcn.nhs.uk
59. Free A. Extending the GSF to non cancer patients. July 2005. Link from http://www.goldstandardsframework.nhs.uk/non_cancer.php
60. Anon Coronary Heart Disease Collaborative Supportive and Palliative Care for Advanced Heart Failure 2005. www.modern.nhs.uk/chd
61. Liverpool Care Pathway for the Dying www.lcp‐mariecurie.org.uk
62. Mueller P S, Hook C C, Hayes D l. Ethical analysis of withdrawal of pacemaker or implantable cardioverter–defibrillator support at the end of life. Mayo Clin Pract 2003. 78959–963.963 [PubMed]
63. Ross H M. Deactivating implantable cardioverter defibrillators/in response. Ann Intern Med 2005. 143690 [PubMed]
64. Berger J T. Deactivating implantable cardioverter defibrillators/in response. Ann Intern Med 2005. 143691 [PubMed]
65. Verma A K, da Silva J H, Kuhl D R. Diuretic effects of subcutaneous furosemide in human volunteers: a randomised pilot study. Ann Pharmacother 2004. 38544–549.549 [PubMed]
66. Goenaga M A. Millet M, Sanchez E, et al. Subcutaneous furosemide. Ann Pharmacother 2004. 381751 [PubMed]
67. Gannon C. Palliative care in terminal cardiac failure; hospices cannot fulfil such a vast and diverse role BMJ1995. 310310–311.311 [PMC free article] [PubMed]
68. Beattie J M, Murray R G, Brittle J. et al Palliative care in terminal cardiac failure. Small numbers of patients with terminal cardiac failure may make considerable demands on services. BMJ 1995. 3101411 [PMC free article] [PubMed]
69. Davidson P M, Paull G, Introna K. et al Integrated, collaborative palliative care in heart failure: the St George Heart Failure Service experience 1999–2002. J Cardiovascular Nursing 2004. 1968–75.75 [PubMed]
70. Johnson M J, Houghton T. Palliative care for patients with heart failure: description of a service. Palliat Med 2006. 20211–214.214 [PubMed]
71. Daley A, Matthews C, Williams A. Heart failure and palliative care services working in partnership: report of a new model of care. Palliat Med 2006. 20593–601.601 [PubMed]
72. Dharmasena H P, Forbes K. Palliative care for patients with non‐malignant disease: will hospital physicians refer? Palliat Med 2001. 15412–481.481 [PubMed]
73. Sykes J, Chester T. Palliative care for chronic heart failure patients. Heart 2003. 89(Suppl 1)A8018
74. Paes P. A pilot study to assess the effectiveness of a palliative care clinic in improving the quality of life for patients with severe heart failure. Palliat Med 2005. 19505–506.506 [PubMed]
75. Gibbs L M E, Khatri A K, Gibbs J S R. Survey of specialist palliative care and heart failure: September 2004. Palliat Med 2006. 20603–609.609 [PubMed]
76. Supportive and Palliative Care in Heart Failure: a resource kit for cardiac networks Heart Improvement Programme. www.heart.nhs.uk Available from NHS Health Improvement Programme 3rd floor, St. John's House, East Street. Leicester LE1 6NB.

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group